299 papers found
Refreshing results…
DNA Methylation Profiling of Sorted Cells from Myelofibrosis Patients reveals Aberrant Epigenetic Regulation of Immune Pathways and identifies Early MPN Driver Genes
Prediagnostic Thrombocytosis Increases the Risk of Advanced Gynecological Cancer and Increases Mortality Independently of Cancer Stage – a Population-Based Study
Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression
The platelet–cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?
Expansion of circulating CD56 bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α
Increasing Red Cell Mass and JAK2 V617F Allele Burden in a Patient with Polycythemia Vera and Normal Bone Marrow Five Years after Discontinuation of Long-term Interferon-Alpha2b
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat
Figure S1
Risk of Lymphoma and Solid Cancer among Patients with Rheumatoid Arthritis in a Primary Care Setting
The Copenhagen Primary Care Differential Count (CopDiff) database
Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state
Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms
Eosinophilia in routine blood samples as a biomarker for solid tumor development – A study based on The Copenhagen Primary Care Differential Count (CopDiff) Database
Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms
A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?
Whole Blood Transcriptional Profi ling Reveals Signifi cant Downregulation of HLA Class I and II Genes in Essential Thrombocythemia, Polycythemia Vera and Myelofi brosis
A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis
Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation
RETRACTED: Eosinophilia in routine blood samples as a biomarker for solid tumor development – A study based on The Copenhagen Primary Care Differential Count (CopDiff) Database
Rapid Clearance Of JAK2 V617F Allele Burden In Patient With Advanced Polycythemia Vera (PV) During Combination Therapy With Ruxolitinib and Peg-Interferon Alpha-2a
Missing publications? Read more about our data sources.